BRAF V600E Mutation Status in Anaplastic Thyroid Carcinoma

被引：0
|
作者：
Nonaka, Daisilke
Rushton, Sarah
Burghel, George
Wallace, Andrew
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] Univ Manchester, Manchester, Lancs, England
[3] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England
来源：
LABORATORY INVESTIGATION | 2015年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
544
引用
收藏
页码：139A / 139A
页数：1
相关论文
共 50 条
  • [31] Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma
    Zagzag, Jonathan
    Pollack, Aron
    Dultz, Linda
    Dhar, Shumon
    Ogilvie, Jennifer B.
    Heller, Keith S.
    Deng, Fang-Ming
    Patel, Kepal N.
    SURGERY, 2013, 154 (06) : 1199 - 1204
  • [32] Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma
    Choi, Eun Kyoung
    Chong, Ari
    Ha, Jung-Min
    Jung, Chan Kwon
    O, Joo Hyun
    Kim, Sung Hoon
    CLINICAL ENDOCRINOLOGY, 2017, 87 (01) : 73 - 79
  • [33] BRAF V600E Mutational Status in Pediatric Thyroid Cancer
    Henke, Lauren E.
    Perkins, Stephanie M.
    Pfeifer, John D.
    Ma, Changquing
    Chen, Yumei
    DeWees, Todd
    Grigsby, Perry W.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (07) : 1168 - 1172
  • [34] BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma
    Affolter, Kajsa
    Samowitz, Wade
    Tripp, Sheryl
    Bronner, Mary P.
    GENES CHROMOSOMES & CANCER, 2013, 52 (08): : 748 - 752
  • [35] An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis
    Behnagh, Arman Karimi
    Eghbali, Maryam
    Abdolmaleki, Fereshteh
    Ghadikolaei, Omolbanin Asadi
    Asl, Parisa Rezazadeh
    Afsharpad, Mandana
    Cheraghi, Sara
    Honardoost, Maryam
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (07) : 1496 - 1507
  • [36] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Lang, Matthias
    Longerich, Thomas
    Anamaterou, Chrysanthi
    THYROID RESEARCH, 2023, 16 (01)
  • [37] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Matthias Lang
    Thomas Longerich
    Chrysanthi Anamaterou
    Thyroid Research, 16
  • [38] A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation
    Pancer, Jill
    Mitmaker, Elliot
    Ajise, Oluyomi
    Tabah, Roger
    How, Jacques
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2019,
  • [39] Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
    Iyer, Priyanka C.
    Cote, Gilbert J.
    Hai, Tao
    Gule-Monroe, Maria
    Bui-Griffith, Jacquelin
    Williams, Michelle D.
    Hess, Kenneth
    Hofmann, Marie-Claude
    Dadu, Ramona
    Zafereo, Mark
    Busaidy, Naifa L.
    Ferrarotto, Renata
    Subbiah, Vivek
    Gross, Neil
    Gunn, Brandon G.
    Skinner, Heath D.
    Garden, Adam S.
    Cabanillas, Maria E.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 11
  • [40] The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer
    Beisa, Augustas
    Beisa, Virgilijus
    Stoskus, Mindaugas
    Ostaneviciute, Elvyra
    Griskevicius, Laimonas
    Strupas, Kestutis
    ENDOKRYNOLOGIA POLSKA, 2016, 67 (01) : 35 - 40
12345